Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK)

Drug Metabolism and Pharmacokinetics

Volumn 23, Issue 5, 2008, Pages 379-384

  Kim, Su Rang ^a   Saito, Yoshiro ^a   Maekawa, Keiko ^a   Sugiyama, Emiko ^a   Kaniwa, Nahoko ^a   Ueno, Hideki ^b   Okusaka, Takuji ^b   Ikeda, Masafumi ^b   Morizane, Chigusa ^b   Yamamoto, Noboru ^c   Yoshida, Teruhiko ^b   Kamatani, Naoyuki ^d   Furuse, Junji ^e   Ishii, Hiroshi ^e,f   Saijo, Nagahiro ^e   Ozawa, Shogo ^a,g   Sawada, Jun Ichi ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f CANCER INSTITUTE HOSPITAL   (Japan)

^g IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

DCK; Ethnic differences; Gemcitabine; Genetic variation; Haplotype

Indexed keywords

DEOXYCYTIDINE KINASE; GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; AMINO ACID SUBSTITUTION; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DNA FLANKING REGION; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; NUCLEIC ACID BASE SUBSTITUTION; NUCLEOTIDE SEQUENCE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN; GENETICS; JAPAN; NEOPLASM;

ANTIMETABOLITES, ANTINEOPLASTIC; ASIAN CONTINENTAL ANCESTRY GROUP; DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; HAPLOTYPES; HUMANS; JAPAN; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 58149302936     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.23.379     Document Type: Article

References (17)

1. Arner, E. S. J. and Eriksson, S.: Mammalian deoxynucleoside kinases. Pharmacol. Ther., 67: 155-186 (1995).
2. Van Rompay, A. R., Johansson, M. and Karlsson, A.: Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases. Pharmacol. Ther., 100: 119-139 (2003).
3. Song, J. J., Walker, S., Chen, E., Johnson, E. E. 2nd, Spychala, J., Gribbin, T. and Mitchell, B. S.: Genomic structure and chromosomal localization of the human deoxycytidine kinase gene. Proc. Natl. Acad. Sci. USA., 90: 431-434 (1993).
4. Chen, E. H., Johnson, E. E. 2nd, Vetter, S. M. and Mitchell, B. S.: Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines. J. Clin. Invest., 95: 1660-1668, (1995).
5. Johansson, M., Norda, A. and Karlsson, A.: Conserved gene structure and transcription factor sites in the human and mouse deoxycytidine kinase genes. FEBS Lett., 487: 209-212 (2000).
6. Ge, Y., Jensen, T.L., Matherly, L. H. and Taub, J. W.: Physical and functional interactions between USF and Sp1 proteins regulate human deoxycytidine kinase promoter activity. J. Biol. Chem., 278: 49901-49910 (2003).
7. Momparler, R. L. and Fischer, G. A.: Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. J. Biol. Chem., 243: 4298-4304 (1968).
8. Spasokoukotskaja, T., Arner, E. S., Brosjo, O., Gunven, P., Juliusson, G., Liliemark, J. and Eriksson, S.: Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human normal and tumour cells and tissues. Eur. J. Cancer, 31A: 202-208 (1995).
9. Hengstschlager, M., Denk, C. and Wawra, E.: Cell cycle regulation of deoxycytidine kinase. Evidence for post-transcriptional control. FEBS Lett., 321: 237-240 (1993).
10. Jordheim, L.P. and Dumontet, C.: Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim. Biophys. Acta, 1776: 138-159 (2007).
11. Manome, Y., Wen, P. Y., Dong, Y., Tanaka, T., Mitchell, B. S., Kufe, D. W. and Fine, H. A.: Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat. Med., 2: 567-573 (1996).
12. Hapke, D. M., Stegmann, A. P. and Mitchell, B.S.: Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res., 56: 2343-2347 (1996).
13. Achiwa, H., Oguri, T., Sato, S., Maeda, H., Niimi, T. and Ueda, R.: Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci., 95: 753-757 (2004).
14. Shi, J. Y., Shi, Z. Z., Zhang, S. J., Zhu, Y. M., Gu, B. W., Li, G., Bai, X. T., Gao, X. D., Hu, J., Jin,W., Huang,W., Chen, Z. and Chen, S. J.: Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics, 14: 759-768 (2004).
15. Joerger, M., Bosch, T. M., Doodeman, V. D., Beijnen, J. H., Smits, P. H. and Schellens, J. H.: Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. Eur. J. Clin. Pharmacol., 62: 681-684 (2006).
16. Lamba, J. K., Crews, K., Pounds, S., Schuetz, E. G., Gresham, J., Gandhi, V., Plunkett, W., Rubnitz, J. and Ribeiro, R.: Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J. Pharmacol. Exp. Ther., 323: 935-945 (2007).
17. Kitamura, Y., Moriguchi, M., Kaneko, H., Morisaki, H., Morisaki, T., Toyama, K. and Kamatani, N.: Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm. Ann. Hum. Genet., 66: 183-193 (2002).